MDT closed the week at $90.77, down 3.2% on the week and roughly 2.8% over the past month, even as the analyst community raised targets in bulk following the company's most recent earnings print.
The disconnect between a softening stock and a freshly upgraded Street is the most interesting tension heading into a quiet pre-earnings stretch — with the next result not due until late November.
The analyst move was broad and unambiguously upward. Following the September 1 earnings release, nearly every major firm on the coverage list raised its price target. UBS lifted to $110, B of A Securities moved from $95 to $110, TD Cowen went to $110 from $100, and Truist bumped its Hold-rated target from $86 to $99. Across the board, consensus sits at Buy with a mean target of $104.83 — implying roughly 15% upside from the current price. Even the skeptics moved. Stifel raised its Hold target from $80 to $95, and Baird nudged its Neutral target from $91 to $100. The direction of travel is clear: the Street thinks the stock is cheap here, even if a meaningful portion of coverage is unwilling to turn outright bullish.
The bear case centers on execution risk and market dynamics rather than near-term numbers. Competition is intensifying across several device categories, and Medtronic's international revenue base carries real currency and regulatory exposure. Organic growth has been sluggish for years, which is part of why acquisition-led narratives are doing much of the fundamental work right now. The earnings history is modestly supportive — the last two prints moved the stock roughly 1.7% and 3.9% higher on the day, with five-day follow-through that quickly faded back. That's not a short-squeeze dynamic; it's a stock that can rally on relief and then drift again.
Short positioning adds almost nothing to this particular story. SI is just under 1% of free float — a negligible level — and has actually fallen 30% over the past month, dropping from around 18 million shares short in mid-August to just over 12.6 million today. Borrowing costs are technically rising, up 80% over the week to 0.85%, but in absolute terms that remains comfortably low. Borrow availability is as loose as it gets, meaning there is no meaningful lending market pressure in either direction. The ORTEX short score sits at 29, well into low-risk territory. Options pricing is incrementally more cautious — the put/call ratio of 0.64 is running about 1.3 standard deviations above its 20-day average, a mild defensive tilt consistent with a stock drifting through macro uncertainty rather than one under active pressure.
On the factor side, MDT scores at the 91st percentile for dividend quality — a relevant consideration for its institutional base, with the yield sitting just above 3%. The 12-month forward EPS growth score ranks in the 74th percentile, consistent with the raised guidance narrative. Days-to-cover ranks in the 73rd percentile, more a reflection of the low short interest than any borrow-driven dynamic. Peer performance this week tells a similar story: ZBH fell 4.5% and RMD dropped 3.3%, suggesting broad device-sector weakness rather than anything company-specific dragging on MDT. ABT and MMSI managed modest gains, indicating the sector is not uniform in its softness.
The setup heading into November earnings is one where the Street has already re-rated higher, the stock has not followed, and short sellers are not pressing the thesis. What matters now is whether MDT can demonstrate the organic growth momentum — and not just the guided line — that would close the gap between the current price and the analyst consensus.
See the live data behind this article on ORTEX.
Open MDT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
